AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Luma Therapeutics Announces Data Presentations from Studies of the Illuvinate System for the Treatment for Plaque Psoriasis at AAD Annual Meeting

February 27, 2019

MILLBRAE, Calif.--(BUSINESS WIRE)--Feb 27, 2019--Luma Therapeutics, a company dedicated to eradicating suffering from inflammatory skin disease, today announced that new data from studies of the company’s illuvinate™ System will be presented at the American Academy of Dermatology Annual Meeting taking place March 1 to 4 in Washington, D.C.

Clinical trials conducted to demonstrate the safety and efficacy of the product will be presented by Tina Bhutani, M.D., of the UCSF Medical Center in San Francisco, Calif., as part of the following presentations (all times local):

  • Phototherapy
    Presented by Henry W. Lim, M.D., Anna Chien, M.D., Benjamin Stoff, M.D., Elizabeth A. Buzney, M.D., and Tina Bhutani, M.D.
    Friday, March 1, 9:00 a.m., Room 201
  • Psoriasis and Atopic Dermatitis: Advances in Immunology and Therapy
    Presented by Jashin J. Wu, M.D., Emma Guttman, M.D., Ph.D., Lawrence F. Eichenfield, M.D., Paul Steven Yamauchi, M.D., Ph.D., Tina Bhutani, M.D.
    Saturday, March 2, 3:30 p.m., Salon H

Luma Therapeutics will also hold a cocktail reception hosted by founder and CEO Evan Anderson and Chief Medical Officer Jeffrey Sugarman, M.D., on Thursday Feb. 28, 4:30 to 7:00 p.m., at Convivial, 801 O Street NW, Washington, D.C. Click here to RSVP.

The company will be exhibiting at the conference in booth #2347.

About the illuvinate™ System

The FDA-cleared illuvinate System is an innovative treatment designed to provide lasting relief from psoriasis symptoms. Inspired by the Goeckerman Regimen, a 100-year-old proven therapy that results in long periods of remission lasting over a year. 1  However this treatment is only available at a handful of specialized centers and often requires multiple day-long clinic visits over a period of weeks, creating barriers to widespread adoption. Luma Therapeutics has redesigned the key elements of the Goeckerman Regimen to make it available to patients in their own home.

Illuvinate has been demonstrated to reduce local inflammation, rehydrate the skin and restore normal skin cells. The system includes patented hydrating technology, a narrowband UV LED light system, and a proprietary app-based dosing algorithm. The therapy is applied for just minutes each day over a six-week period from the comfort and convenience of home. The system can now be prescribed either by a dermatologist or via Luma’s telehealth provider,  HealthLens.

About Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical technology company committed to developing innovative and convenient therapies for the millions of people around the world suffering from inflammatory skin disease. In collaboration with Mayo Clinic, Luma Therapeutics developed the FDA-cleared illuvinate™ System to offer patients with psoriasis an effective treatment option that can be used at home. The company has also been supported by StartX accelerator and the Rosenman Institute at QB3. For more information visit www.lumatherapuetics.com.

1 Gupta, Rishu, et al. “The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis.”  Journal of Visualized Experiments, no. 77, 2013, doi:10.3791/50509.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005959/en/

CONTACT: Durae Hardy

Health+Commerce

Tel: 707.337.1903

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA DISTRICT OF COLUMBIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES GENERAL HEALTH

SOURCE: Luma Therapeutics

Copyright Business Wire 2019.

PUB: 02/27/2019 04:10 PM/DISC: 02/27/2019 04:10 PM

http://www.businesswire.com/news/home/20190227005959/en

All contents © copyright 2019 The Associated Press. All rights reserved.